LENSAR Inc (LNSR)vsStryker Corporation (SYK)
LNSR
LENSAR Inc
$7.60
-5.59%
HEALTHCARE · Cap: $101.36M
SYK
Stryker Corporation
$275.56
+2.31%
HEALTHCARE · Cap: $105.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 42773% more annual revenue ($25.84B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 14.4%. SYK trades at a lower P/E of 28.0x. SYK earns a higher WallStSmart Score of 67/100 (B-).
LNSR
Buy51
out of 100
Grade: C-
SYK
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.5%
Fair Value
$6.73
Current Price
$7.60
$0.87 premium
Margin of Safety
-19.9%
Fair Value
$229.73
Current Price
$275.56
$45.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Generating 1.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score. A P/E of 43.4x leaves little room for execution misses.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LNSR profiles as a growth stock while SYK is a value play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.88 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (67/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?